The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome

Damien A. Leach, Andrew P. Trotta, Eleanor F. Need, Gail P. Risbridger, Renea A. Taylor, Grant Buchanan

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

BACKGROUND: Improving our ability to predict cancer progression and response to conservative or radical intent therapy is critical if we are to prevent under or over treatment of individual patients. Whereas the majority of solid tumors now have a range of molecular and/or immunological markers to help define prognosis and treatment options, prostate cancer still relies mainly on histological grading and clinical parameters. We have recently reported that androgen receptor (AR) expression in stroma inversely associates with prostate cancer-specific survival, and that stromal AR reduces metastasis. For this paper, we tested the hypothesis that the AR-regulated gene FKBP51 could be used as a marker of AR activity to better predict outcome. METHODS: Using immunohistochemistry on a cohort of 64 patient-matched benign and malignant prostate tissues, we assessed patient outcome by FKBP51 and AR levels. Immunoblot and RT-qPCR were used to demonstrate androgen regulation of FKBP51 in primary and primary human prostatic fibroblasts and fibroblast cell-lines. RESULTS. As predicted by FKBP51 level, high AR activity in cancer stroma was associated with longer median survival (1,306 days) compared with high AR alone (699 days), whereas those with low AR and/or low FKBP51 did poorly (384 and 338 days, respectively). Survival could not be predicted on the basis cancer epithelial AR levels or activity, and was not associated with immunoreactivity in patient matched benign tissues. CONCLUSION: FKBP51 improves the ability of stromal AR to predict prostate cancer-specific mortality. By adding additional immunological assessment, similar to what is already in place in a number of other cancers, we could better serve patients with prostate cancer in prognosis and informed treatment choices.
Original languageEnglish
Pages (from-to)185-195
Number of pages11
JournalProstate
Volume77
Issue number2
DOIs
Publication statusPublished - 1 Feb 2017

Keywords

  • androgen receptor
  • fibroblasts
  • FK506-binding protein 1
  • prostate cancer
  • stroma

Cite this

Leach, Damien A. ; Trotta, Andrew P. ; Need, Eleanor F. ; Risbridger, Gail P. ; Taylor, Renea A. ; Buchanan, Grant. / The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome. In: Prostate. 2017 ; Vol. 77, No. 2. pp. 185-195.
@article{5dcec130be35407789919f5d7bbbce26,
title = "The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome",
abstract = "BACKGROUND: Improving our ability to predict cancer progression and response to conservative or radical intent therapy is critical if we are to prevent under or over treatment of individual patients. Whereas the majority of solid tumors now have a range of molecular and/or immunological markers to help define prognosis and treatment options, prostate cancer still relies mainly on histological grading and clinical parameters. We have recently reported that androgen receptor (AR) expression in stroma inversely associates with prostate cancer-specific survival, and that stromal AR reduces metastasis. For this paper, we tested the hypothesis that the AR-regulated gene FKBP51 could be used as a marker of AR activity to better predict outcome. METHODS: Using immunohistochemistry on a cohort of 64 patient-matched benign and malignant prostate tissues, we assessed patient outcome by FKBP51 and AR levels. Immunoblot and RT-qPCR were used to demonstrate androgen regulation of FKBP51 in primary and primary human prostatic fibroblasts and fibroblast cell-lines. RESULTS. As predicted by FKBP51 level, high AR activity in cancer stroma was associated with longer median survival (1,306 days) compared with high AR alone (699 days), whereas those with low AR and/or low FKBP51 did poorly (384 and 338 days, respectively). Survival could not be predicted on the basis cancer epithelial AR levels or activity, and was not associated with immunoreactivity in patient matched benign tissues. CONCLUSION: FKBP51 improves the ability of stromal AR to predict prostate cancer-specific mortality. By adding additional immunological assessment, similar to what is already in place in a number of other cancers, we could better serve patients with prostate cancer in prognosis and informed treatment choices.",
keywords = "androgen receptor, fibroblasts, FK506-binding protein 1, prostate cancer, stroma",
author = "Leach, {Damien A.} and Trotta, {Andrew P.} and Need, {Eleanor F.} and Risbridger, {Gail P.} and Taylor, {Renea A.} and Grant Buchanan",
year = "2017",
month = "2",
day = "1",
doi = "10.1002/pros.23259",
language = "English",
volume = "77",
pages = "185--195",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Blackwell",
number = "2",

}

The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome. / Leach, Damien A.; Trotta, Andrew P.; Need, Eleanor F.; Risbridger, Gail P.; Taylor, Renea A.; Buchanan, Grant.

In: Prostate, Vol. 77, No. 2, 01.02.2017, p. 185-195.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome

AU - Leach, Damien A.

AU - Trotta, Andrew P.

AU - Need, Eleanor F.

AU - Risbridger, Gail P.

AU - Taylor, Renea A.

AU - Buchanan, Grant

PY - 2017/2/1

Y1 - 2017/2/1

N2 - BACKGROUND: Improving our ability to predict cancer progression and response to conservative or radical intent therapy is critical if we are to prevent under or over treatment of individual patients. Whereas the majority of solid tumors now have a range of molecular and/or immunological markers to help define prognosis and treatment options, prostate cancer still relies mainly on histological grading and clinical parameters. We have recently reported that androgen receptor (AR) expression in stroma inversely associates with prostate cancer-specific survival, and that stromal AR reduces metastasis. For this paper, we tested the hypothesis that the AR-regulated gene FKBP51 could be used as a marker of AR activity to better predict outcome. METHODS: Using immunohistochemistry on a cohort of 64 patient-matched benign and malignant prostate tissues, we assessed patient outcome by FKBP51 and AR levels. Immunoblot and RT-qPCR were used to demonstrate androgen regulation of FKBP51 in primary and primary human prostatic fibroblasts and fibroblast cell-lines. RESULTS. As predicted by FKBP51 level, high AR activity in cancer stroma was associated with longer median survival (1,306 days) compared with high AR alone (699 days), whereas those with low AR and/or low FKBP51 did poorly (384 and 338 days, respectively). Survival could not be predicted on the basis cancer epithelial AR levels or activity, and was not associated with immunoreactivity in patient matched benign tissues. CONCLUSION: FKBP51 improves the ability of stromal AR to predict prostate cancer-specific mortality. By adding additional immunological assessment, similar to what is already in place in a number of other cancers, we could better serve patients with prostate cancer in prognosis and informed treatment choices.

AB - BACKGROUND: Improving our ability to predict cancer progression and response to conservative or radical intent therapy is critical if we are to prevent under or over treatment of individual patients. Whereas the majority of solid tumors now have a range of molecular and/or immunological markers to help define prognosis and treatment options, prostate cancer still relies mainly on histological grading and clinical parameters. We have recently reported that androgen receptor (AR) expression in stroma inversely associates with prostate cancer-specific survival, and that stromal AR reduces metastasis. For this paper, we tested the hypothesis that the AR-regulated gene FKBP51 could be used as a marker of AR activity to better predict outcome. METHODS: Using immunohistochemistry on a cohort of 64 patient-matched benign and malignant prostate tissues, we assessed patient outcome by FKBP51 and AR levels. Immunoblot and RT-qPCR were used to demonstrate androgen regulation of FKBP51 in primary and primary human prostatic fibroblasts and fibroblast cell-lines. RESULTS. As predicted by FKBP51 level, high AR activity in cancer stroma was associated with longer median survival (1,306 days) compared with high AR alone (699 days), whereas those with low AR and/or low FKBP51 did poorly (384 and 338 days, respectively). Survival could not be predicted on the basis cancer epithelial AR levels or activity, and was not associated with immunoreactivity in patient matched benign tissues. CONCLUSION: FKBP51 improves the ability of stromal AR to predict prostate cancer-specific mortality. By adding additional immunological assessment, similar to what is already in place in a number of other cancers, we could better serve patients with prostate cancer in prognosis and informed treatment choices.

KW - androgen receptor

KW - fibroblasts

KW - FK506-binding protein 1

KW - prostate cancer

KW - stroma

UR - http://www.scopus.com/inward/record.url?scp=84991113241&partnerID=8YFLogxK

U2 - 10.1002/pros.23259

DO - 10.1002/pros.23259

M3 - Article

AN - SCOPUS:84991113241

VL - 77

SP - 185

EP - 195

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 2

ER -